All three models agree that LLY is positioned for upside driven by the Phase 3 TRIUMPH-2 and TRIUMPH-3 retatrutide data showing 22.6% weight loss and the upcoming August 5th Q2 earnings catalyst. Technical momentum is confirmed by all models as price reclaims the $1182-$1189 support zone with rising RSI and MACD indicators, targeting a retest of the $1234-$1245 resistance shelf. One model specifically highlights LLY's history of significant earnings beats (+25.9%, +19.2%) and sector confirmation from XLV as additional tailwinds for a 1-3 week breakout.
All three models warn that LLY is tactically overextended near its 52-week high of $1249.45, with 30-minute RSI levels hitting overbought territory (70+) and price stalling at the upper Bollinger Band. Two models argue the retatrutide catalyst is already priced in, suggesting a low-conviction rally on depressed volume (z-score -2.74) that risks a mean-reversion move toward the $1109-$1155 high-volume nodes. Unique risks include a bearish broader macro regime and upcoming US Q2 GDP data, which could trigger a rejection at the $1200-$1237 resistance zone back toward the $1182 SMA 20 support.
- →A 4h close below $1189.07 or failure to hold the $1182-$1189 support zone signals a breakdown in bullish momentum and confirms a resistance-rejection thesis.
- →A daily close below $1182 or a 4h close below $1164 (loss of SMA20 and structural support) invalidates the support-retest thesis and confirms the bounce has failed.
Individual Model Analysis
Bull/Bear CompetitionWinner: BULL
LLY is in a strong uptrend above all key moving averages with fresh positive catalysts: Phase 3 retatrutide data showing up to 22.6% weight loss and a Q2 earnings print Aug 5 backed by a history of large beats (+25.9%, +19.2%). Sector (XLV) and rates (TLT) are confirming the move, and a hold above nearby 4h support $1189 with rising RSI/MACD momentum supports continuation toward the $1234-1244 resistance shelf over the next 1-3 weeks.
LLY is stalling near the upper end of its range (-3.9% from 52-week high) with 30-minute RSI at 70 (overbought) into a high-impact US Q2 GDP print within 3 days and a mildly bearish equity regime, setting up a potential short-term rejection back toward the $1182 support/SMA 20 zone and the value-area body. If price fails to accept above $1200 and rolls over, mean reversion from a stretched intraday extension plus counter-trend regime pressure could drag it toward the $1151-1155 high-volume node cluster. The short works only as a tactical fade of an intraday overbought push, not a structural breakdown.
Bull/Bear CompetitionWinner: BULL
LLY is in a support-retest-reclaim setup after bouncing from the $1182- $1189 zone (4h SMA 20/SMA 50 cluster) and is now pushing higher with improving momentum. The fresh retatrutide Phase 3 data (TRIUMPH-2/3, Jul 23) provides a catalyst tailwind, and the upcoming Q2 earnings on Aug 5 adds event-driven interest. With XLV confirming the move and the stock reclaiming its key moving averages, the path targets a retest of the $1240- $1245 resistance zone (near 52-week highs) over the next 1-3 weeks.
LLY is rallying into the $1200- $1245 resistance zone on depressed volume (z-score -2.74) , with the 30-min RSI already overbought at 70.23 and price pinned at the upper Bollinger Band — a classic low-conviction extension that typically reverses. The bearish macro regime (dollar strength, tech weakness, flight-to-safety) provides a tailwind for shorts, while the prior failed long at $1237 resistance confirms the barrier's credibility. With earnings not due until Aug 5 and the retatrutide catalyst already priced, the path of least resistance is a mean-reversion grind back toward the value area low near $1109 and the 30-day POC at $1117.
Bull/Bear CompetitionWinner: BULL
LLY presents a compelling long case driven by a fresh catalyst: the Phase 3 TRIUMPH-2 and TRIUMPH-3 trial results for retatrutide, showing average weight loss up to 22.6%, which positions the drug as a potential blockbuster in the obesity market. This news, combined with the upcoming Q2 2026 earnings release on August 5, provides a near-term catalyst for upside repricing. Technically, LLY is showing bullish momentum with RSI rising and MACD histogram turning positive, suggesting further upside potential. The stock is currently trading near support at $1189.07, with a clear path to resistance at $1243.93, aligning with the broader Healthcare sector's strength.
LLY is positioned for a short swing trade due to its extended price location near all-time highs, weakening momentum, and overbought technical conditions. The stock is trading just below its 52-week high of $1249.45 (-3.9%) and faces immediate resistance at $1234.65 (4h) and $1243.93 (1day), with no fresh catalysts to justify a breakout. The broader market regime is bearish, and LLY's recent outperformance lacks confirmation from sector peers, increasing the risk of a pullback toward support at $1140.00 or lower.